Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02761187 · ClinicalTrials.gov registry record
An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants
A clinical trial, sponsored by Takeda.
- Terminated
- Registry status
- 4,253
- Enrollment target
NCT02761187: Clinical Trial study, sponsored by Takeda.
NCT02761187 is a clinical trial that was terminated before completion, run by Takeda. The registered enrollment target is 4,253 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02761187 was terminated before completion, sponsored by Takeda.
- TERMINATED
- Registry status
- 4,253 participants
- Enrollment target
Study Summary
The purpose of this study is to describe contemporary, real-world patterns of participant characteristics, clinical disease presentation, therapeutic regimen chosen, and clinical outcomes in participants with newly diagnosed \[ND\] multiple myeloma (MM) and participants with relapsed/refractory \[R/R\] MM.
Primary Outcome
Charlson Comorbidity Index (CCI) was used to represent number of participants with co-morbidities. CCI is a method of categorizing comorbidities of participants. Each comorbidity category has an associated weight (from 1 to 6), based on the adjusted risk of mortality or resource use, and the sum of all the weights results in a single comorbidity score for a participant. A score of 0 = no comorbidities found, 1 = not ill, 2 = mildly ill, 3 = moderately ill, 4 = severely ill, and ≥5 = moribund. Th
Interventions
- OTHER No Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,253 participants |
| Start Date | 2016-07-01 |
| Est. Completion | 2021-09-30 |
Why NCT02761187 stopped before completion
NCT02761187 is an observational study that tracks outcomes without assigning an intervention. Its 4,253 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which No Intervention is the first listed.
NCT02761187 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02761187 about?
NCT02761187 is a clinical study titled "An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants". The purpose of this study is to describe contemporary, real-world patterns of participant characteristics, clinical disease presentation, therapeutic regimen chosen, and clinical outcomes in participants with newly diagnosed \[ND\] multiple myeloma (MM) and participants with relapsed/refractory \[R/...
What is the current status of trial NCT02761187?
This trial is currently terminated. The enrollment target is 4,253 participants. The study started on 2016-07-01. Estimated completion is 2021-09-30.
What interventions are being tested in trial NCT02761187?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT02761187?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06492616 · 4,220 participants · Phase 3
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- NCT05543616 · 4,292 participants · Phase 2
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
- NCT05774951 · 4,300 participants · Phase 3
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
- NCT02693535 · 4,200 participants · Phase 2
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI